Filing Details
- Accession Number:
- 0001104659-24-010826
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-05 21:23:02
- Reporting Period:
- 2024-02-02
- Accepted Time:
- 2024-02-05 21:23:02
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1773427 | Springworks Therapeutics Inc. | SWTX | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1819465 | Daniel Pichl | C/O Springworks Therapeutics, Inc. 100 Washington Blvd. Stamford CT 06902 | Chief People Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-02-02 | 16,250 | $27.64 | 71,393 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-02-02 | 9,266 | $43.81 | 62,127 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-02-02 | 14,175 | $44.31 | 47,952 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-02-02 | 1,997 | $45.95 | 45,955 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-02-02 | 743 | $46.44 | 45,212 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2024-02-02 | 16,250 | $0.00 | 16,250 | $27.64 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
48,750 | 2033-01-05 | No | 4 | M | Direct |
Footnotes
- The transactions reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on March 9, 2023.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.05 to $44.045. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.05 to $44.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.29 to $46.23. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.31 to $47.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- Twenty-five percent (25%) of this option shall vest and become exercisable on January 5, 2024, with the remaining seventy-five percent (75%) to vest in thirty-six (36) equal monthly installments thereafter subject to continued service to the Issuer by the Reporting Person.